The BCMA-targeting humanized bispecific monoclonal antibody elranatamab elicited high response rates when subcutaneously delivered at higher doses in patients with relapsed/refractory multiple myeloma.
Recent Content
- Real-world clinical outcomes of autologous stem cell transplantation in Chinese patients with newly diagnosed multiple myeloma: a systematic literature review
- FDA approves electrical field therapy Optune Pax for pancreatic cancer
- (no title)
- (no title)
- Trial of glioma drug safusidenib to add patients, move to Phase 3
- Ovarian cancer drug lira-cel extends survival ‘far longer’ than expected
- The impact of cardiac amyloidosis on patients with multiple myeloma: a systematic review and meta-analysis
- (no title)
- Myeloma treatment anito-cel shows potential for fewer side effects
- FDA grants orphan drug status to new treatment for agressive blood cancers